Epitalon Research: What 140 Studies Show (2026) | RetatrutideCompare

Epitalon — 140 studies indexed on PubMed. Proposed to up-regulate telomerase activity and modulate gene expression in pinealocytes; binds DNA in vitro. Half-life: Minutes in plasma; epigenetic effects suggested to persist. FDA status: Not FDA-approved.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Epitalon?

There are approximately 140 studies indexed on PubMed that mention Epitalon (Epithalon, AEDG), based on a search last updated 2026-06-18.

Is Epitalon FDA-approved?

FDA status: Not FDA-approved.

How does Epitalon work?

Proposed to up-regulate telomerase activity and modulate gene expression in pinealocytes; binds DNA in vitro.

Proposed to up-regulate telomerase activity and modulate gene expression in pinealocytes; binds DNA in vitro.

Reference facts

Also known as
Epithalon, AEDG, Epitalamin fragment
Category
Khavinson Bioregulators
Mechanism of action
Proposed to up-regulate telomerase activity and modulate gene expression in pinealocytes; binds DNA in vitro.
Targets
Telomerase (proposed), DNA-binding
Indications under research or approved
Russian gerontology research; not US-approved
Regulatory status (reference entry)
Not FDA-approved
Half-life
Minutes in plasma; epigenetic effects suggested to persist
Sequence
AEDG
Sequence notes
Tetrapeptide developed by V. Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.
Molecular weight (Da)
390
Originator / sponsor
Khavinson Peptides (Russia)
First reported
1990

Primary References

Explore research articles about Epitalon

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.